EICHOR
● Completed
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer · Sponsor: Genentech, Inc.
About this study
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (40)
| Arizona Oncology Associates, PC - HAL | Tempe, Arizona, United States | — |
| SCRI Florida Cancer Specialists South | Fort Myers, Florida, United States | — |
| Florida Cancer Specialists - NORTH - SCRI - PPDS | St. Petersburg, Florida, United States | — |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | — |
| Illinois Cancer Care | Peoria, Illinois, United States | — |
| University of Kansas Medical Center | Westwood, Kansas, United States | — |
| Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Research Medical Center | Kansas City, Missouri, United States | — |
| SCRI Tennessee Oncology | Nashville, Tennessee, United States | — |
| Virginia Cancer Specialists, PC | Fairfax, Virginia, United States | — |
| Northwest Cancer Specialists - Vancouver | Vancouver, Washington, United States | — |
| ICO Paul Papin | Angers, France | — |
+ 28 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03563716